| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
HDAC-IN-4 (also known as CXD101, AZD9468) is a novel and potent inhibitor of histone deacetylase (HDAC) with potential anticancer and immunomodulatory activity. It is taken from the 20070426 patent WO/2007045844 A1. Learning and memory as well as synaptic plasticity have been linked to the family of enzymes known as histone deacetylases (HDACs), which play a role in epigenetic regulation. The structures of HDAC-IN-4 and mocetinostat, MS-275, and JNJ-26481585 are similar.
| Targets |
HDAC1 ( IC50 = 63 nM ); HDAC3 ( IC50 = 550 nM ); HDAC2 ( IC50 = 570 nM )
|
|---|---|
| ln Vitro |
Zabadinostat has been examined in vitro using cell lines from non-Hodgkin lymphoma, colon, lung, and myeloma, with IC50 values ranging from 0.2 to 15 μM[2].
|
| ln Vivo |
Zabadinostat significantly reduces the size of tumors in murine xenograft lung (A549a) and colon (HT29) models when administered at a dose of 50 mg/kg. It has been discovered that reduced HDAC enzyme activity and elevated histone acetylation are linked to tumor reductions[2]. For Zabadinostat, terminal half-lives are 6 and 8 hours, respectively, and peak plasma concentrations (Cmax) are reached 1 to 2 hours after oral dosing in murine and canine models. Tissue radioactivity peaked three to six hours after oral [14C]-Zabadinostat (1.6 mg/kg; 4 μmol/kg) was administered to mice. There was still Zabadinostat-related material in the tissue twenty-one days after the dose[2].
|
| References | |
| Additional Infomation |
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Zabadinostat is a novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins. |
| Molecular Formula |
C24H29N5O
|
|
|---|---|---|
| Molecular Weight |
403.519964933395
|
|
| Exact Mass |
403.25
|
|
| Elemental Analysis |
C, 71.44; H, 7.24; N, 17.36; O, 3.96
|
|
| CAS # |
934828-12-3
|
|
| Related CAS # |
|
|
| PubChem CID |
16225380
|
|
| Appearance |
White to off-white solid powder
|
|
| LogP |
2.9
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
30
|
|
| Complexity |
556
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
JHDZMASHNBKTPS-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C24H29N5O/c1-17-21(15-28(2)27-17)16-29-13-11-19(12-14-29)18-7-9-20(10-8-18)24(30)26-23-6-4-3-5-22(23)25/h3-10,15,19H,11-14,16,25H2,1-2H3,(H,26,30)
|
|
| Chemical Name |
N-(2-aminophenyl)-4-[1-[(1,3-dimethylpyrazol-4-yl)methyl]piperidin-4-yl]benzamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4782 mL | 12.3910 mL | 24.7819 mL | |
| 5 mM | 0.4956 mL | 2.4782 mL | 4.9564 mL | |
| 10 mM | 0.2478 mL | 1.2391 mL | 2.4782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA